Taken together, these data indicate that JH295 treatment can sensitize both viral and nonviral lymphomas to chemotherapeutics currently in clinical use, and that NEK2 inhibition represents a potent anti-PEL strategy as both a monotherapy and as part of a synergistic combination therapy. The gene discussed is NEK2; the disease is lymphoma.